Sanofi Chimie to manufacture Pharming's Ruconest following scale-up validation
This article was originally published in Scrip
Executive Summary
Following the recent positive opinion from the EU's CHMP for Pharming's Ruconest (recombinant human C1 inhibitor) for the treatment of angioedema attacks, the Dutch company has signed a toll manufacturing agreement with Sanofi Chimie, a wholly-owned subsidiary of Sanofi-Aventis, aimed at increasing the production capacity of the drug substance within Ruconest.